Concepedia

Jimmy Fourtounis

JF

Statistics

Publications

4

Citations

346

H-Index

4

Active since

2021

Affiliations

Lunenfeld-Tanenbaum Research Institute(Current)

University of Toronto

Mount Sinai Hospital

Telesta Therapeutics (Canada)

Jimmy Fourtounis is an author at Lunenfeld-Tanenbaum Research Institute specializing in synthetic lethality, cdk inhibitors, and oncogene amplification.

Publications per year

2021–2025

4

Publications

4

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

David Gallo, Jordan T.F. Young, Jimmy Fourtounis et al. · Nature · 2022 · 229 citations · Full text

, , +17

Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306

Janek Szychowski, Robert Papp, Evelyne Dietrich et al. · Journal of Medicinal Chemistry · 2022 · 72 citations · Full text

, , +14

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR

Haineng Xu, Erin George, David Gallo et al. · Nature Communications · 2025 · 23 citations · Full text

, , +17

CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition

David Gallo, Jordan T.F. Young, Jimmy Fourtounis et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 22 citations · Full text

, , +17

1–4 of 4